Analysts expect Teradata Corporation (NYSE:TDC) to report $0.05 EPS on May, 3 after the close.They anticipate $0.15 EPS change or 75.00% from last quarter’s $0.2 EPS. TDC’s profit would be $6.05 million giving it 204.65 P/E if the $0.05 EPS is correct. After having $0.44 EPS previously, Teradata Corporation’s analysts see -88.64% EPS growth. The stock decreased 1.16% or $0.48 during the last trading session, reaching $40.93. About 122,251 shares traded. Teradata Corporation (NYSE:TDC) has risen 30.12% since April 20, 2017 and is uptrending. It has outperformed by 18.57% the S&P500.
Casi Pharmaceuticals Inc (NASDAQ:CASI) had an increase of 7.32% in short interest. CASI’s SI was 1.40M shares in April as released by FINRA. Its up 7.32% from 1.30 million shares previously. With 319,200 avg volume, 4 days are for Casi Pharmaceuticals Inc (NASDAQ:CASI)’s short sellers to cover CASI’s short positions. The SI to Casi Pharmaceuticals Inc’s float is 5.1%. The stock increased 0.58% or $0.04 during the last trading session, reaching $6.93. About 164,705 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 181.56% since April 20, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.
Investors sentiment increased to 1.9 in 2017 Q4. Its up 0.76, from 1.14 in 2017Q3. It improved, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 7 reduced holdings. 11 funds opened positions while 8 raised stakes. 3.56 million shares or 48.97% more from 2.39 million shares in 2017Q3 were reported. Virtu Financial Limited Liability accumulated 12,124 shares. Deutsche Bancshares Ag reported 1,721 shares. Northern Corporation accumulated 73,987 shares. Susquehanna Llp reported 0% stake. Citadel Ltd Liability Corporation reported 18,398 shares. Barclays Public Lc invested in 66,720 shares or 0% of the stock. Jpmorgan Chase Company holds 9 shares or 0% of its portfolio. Atlantic Tru Gp Ltd Llc reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris And Ca has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Raymond James Fincl reported 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Blackrock holds 386,090 shares or 0% of its portfolio. Goldman Sachs Gru accumulated 18,861 shares or 0% of the stock. Moreover, Millennium Management Ltd Company has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 42,214 shares. Perceptive Advsr Ltd Liability Company stated it has 83,682 shares or 0.01% of all its holdings. 2,871 are owned by Manufacturers Life Ins Company The.
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $551.92 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 6 analyst reports since October 29, 2015 according to SRatingsIntel. Maxim Group maintained it with “Buy” rating and $400 target in Monday, August 14 report. H.C. Wainwright initiated it with “Buy” rating and $3 target in Thursday, October 29 report. H.C. Wainwright maintained the shares of CASI in report on Wednesday, April 4 with “Buy” rating. The firm has “Buy” rating given on Thursday, September 22 by Maxim Group. H.C. Wainwright maintained CASI Pharmaceuticals, Inc. (NASDAQ:CASI) on Tuesday, January 16 with “Buy” rating.
Among 21 analysts covering Teradata Corporation (NYSE:TDC), 4 have Buy rating, 7 Sell and 10 Hold. Therefore 19% are positive. Teradata Corporation had 56 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Teradata Corporation (NYSE:TDC) earned “Sell” rating by Mizuho on Wednesday, July 26. The firm earned “Sector Perform” rating on Friday, August 7 by RBC Capital Markets. The firm has “Hold” rating given on Friday, August 4 by RBC Capital Markets. Atlantic Securities downgraded the stock to “Overweight” rating in Friday, August 28 report. BMO Capital Markets maintained Teradata Corporation (NYSE:TDC) on Friday, November 3 with “Market Perform” rating. The rating was maintained by Bank of America on Friday, February 9 with “Buy”. The rating was maintained by Mizuho with “Sell” on Wednesday, November 1. Mizuho maintained Teradata Corporation (NYSE:TDC) rating on Thursday, September 28. Mizuho has “Sell” rating and $26.0 target. Cowen & Co maintained the stock with “Hold” rating in Thursday, October 26 report. Mizuho downgraded the stock to “Underperform” rating in Friday, February 10 report.
Teradata Corporation provides analytic data solutions and related services in North America, Latin America, Europe, the Middle East, Africa, the Asia Pacific, and Japan. The company has market cap of $4.95 billion. The firm operates through Americas Data and Analytics, and International Data and Analytics divisions. It currently has negative earnings. The Company’s analytic data solutions comprise software, hardware, and related business consulting and support services for data warehousing, big data, and tools for data integration, data discovery, and business intelligence.
Investors sentiment increased to 0.8 in 2017 Q4. Its up 0.23, from 0.57 in 2017Q3. It is positive, as 18 investors sold Teradata Corporation shares while 122 reduced holdings. 52 funds opened positions while 60 raised stakes. 123.11 million shares or 3.07% less from 127.01 million shares in 2017Q3 were reported. Bnp Paribas Asset Mgmt Hldg Sa invested 0.02% of its portfolio in Teradata Corporation (NYSE:TDC). Stone Ridge Asset Mngmt Lc owns 63,141 shares for 0.16% of their portfolio. Moreover, Spectrum Management has 0.01% invested in Teradata Corporation (NYSE:TDC). Winslow Evans And Crocker, Massachusetts-based fund reported 212 shares. Columbia Ptnrs L L C Mgmt accumulated 37,298 shares or 0.19% of the stock. First Manhattan owns 99 shares. Parametric Lc has invested 0.02% in Teradata Corporation (NYSE:TDC). Liberty Mutual Gp Asset Inc reported 0.04% in Teradata Corporation (NYSE:TDC). North Star Invest Mngmt reported 8,126 shares stake. Gw Henssler And Limited, Georgia-based fund reported 6,761 shares. Advantus Capital Management reported 14,903 shares. Alyeska Investment Grp L P invested 0.01% of its portfolio in Teradata Corporation (NYSE:TDC). Covington Capital Mngmt holds 0% of its portfolio in Teradata Corporation (NYSE:TDC) for 1,500 shares. Thrivent Fincl For Lutherans stated it has 0.25% of its portfolio in Teradata Corporation (NYSE:TDC). 6.91 million were reported by Wellington Mngmt Gp Ltd Liability Partnership.